Distributions in CEA Doubling Time Differ in Patients with Recurrent Colorectal Carcinomas

Manabu Yamamoto, Yoshihiko Maehara, Yoshihisa Sakaguchi, Hiroyuki Mine, Takeharu Yamanaka, Daisuke Korenaga, Takeshi Okamura

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background/Aims: Serum carcinoembryonic antigen (CEA) is often measured during follow-up of patients surgically treated for colorectal cancer. We determined characteristic findings in serum CEA concentrations or CEA doubling time (DT) depending on the different tumor distributions in colorectal cancer patients. Methodology: Serum CEA levels were measured monthly until the patients expired in 32 colorectal cancers after operations. CEA DT was based on semilogarithmic plots of time courses of CEA concentrations. Results: In cases who were preoperatively CEA positive, the maximum serum CEA levels for proximal colon, distal colon and rectal cancers were 384.8± 586.1ng/mL, 1395.7±1954.6ng/mL and 1343.4± 1478.3ng/mL, respectively. The maximum serum CEA level in cases of the proximal colon in preoperative CEA positive patients was lower than that in cases of distal colon or rectum. The average CEA DT on the proximal colon, distal colon and rectal cancers was 71.62±43.77 days, 31.07±15.98 days and 73.97±36.66 days, respectively. The CEA DT with distal colon cancers was also significantly shorter than that with proximal colon or rectal cancers (p<0.05, p<0.02). The CEA DT for lung metastasis was significantly longer than that for liver metastasis, locally or lymph node metastasis or multiple metastases (p<0.02, p<0.02, p<0.001). Conclusions: CEA DT serves to predict life expectancy for patients with recurrent colorectal cancers with different tumor distributions. We propose that precise measurements of serum CEA are needed so as not to overlook recurrent tumors. Detailed follow-up after operations is necessary for such patients, that CEA DT was noted in case of distal colon cancers.

Original languageEnglish
Pages (from-to)147-151
Number of pages5
JournalHepato-gastroenterology
Volume51
Issue number55
Publication statusPublished - Jan 1 2004

Fingerprint

Carcinoembryonic Antigen
Colorectal Neoplasms
Colonic Neoplasms
Colon
Rectal Neoplasms
Serum
Neoplasm Metastasis
Neoplasms
Life Expectancy
Rectum

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Yamamoto, M., Maehara, Y., Sakaguchi, Y., Mine, H., Yamanaka, T., Korenaga, D., & Okamura, T. (2004). Distributions in CEA Doubling Time Differ in Patients with Recurrent Colorectal Carcinomas. Hepato-gastroenterology, 51(55), 147-151.

Distributions in CEA Doubling Time Differ in Patients with Recurrent Colorectal Carcinomas. / Yamamoto, Manabu; Maehara, Yoshihiko; Sakaguchi, Yoshihisa; Mine, Hiroyuki; Yamanaka, Takeharu; Korenaga, Daisuke; Okamura, Takeshi.

In: Hepato-gastroenterology, Vol. 51, No. 55, 01.01.2004, p. 147-151.

Research output: Contribution to journalArticle

Yamamoto, M, Maehara, Y, Sakaguchi, Y, Mine, H, Yamanaka, T, Korenaga, D & Okamura, T 2004, 'Distributions in CEA Doubling Time Differ in Patients with Recurrent Colorectal Carcinomas', Hepato-gastroenterology, vol. 51, no. 55, pp. 147-151.
Yamamoto M, Maehara Y, Sakaguchi Y, Mine H, Yamanaka T, Korenaga D et al. Distributions in CEA Doubling Time Differ in Patients with Recurrent Colorectal Carcinomas. Hepato-gastroenterology. 2004 Jan 1;51(55):147-151.
Yamamoto, Manabu ; Maehara, Yoshihiko ; Sakaguchi, Yoshihisa ; Mine, Hiroyuki ; Yamanaka, Takeharu ; Korenaga, Daisuke ; Okamura, Takeshi. / Distributions in CEA Doubling Time Differ in Patients with Recurrent Colorectal Carcinomas. In: Hepato-gastroenterology. 2004 ; Vol. 51, No. 55. pp. 147-151.
@article{608b236c94354065b9f9447021f169d8,
title = "Distributions in CEA Doubling Time Differ in Patients with Recurrent Colorectal Carcinomas",
abstract = "Background/Aims: Serum carcinoembryonic antigen (CEA) is often measured during follow-up of patients surgically treated for colorectal cancer. We determined characteristic findings in serum CEA concentrations or CEA doubling time (DT) depending on the different tumor distributions in colorectal cancer patients. Methodology: Serum CEA levels were measured monthly until the patients expired in 32 colorectal cancers after operations. CEA DT was based on semilogarithmic plots of time courses of CEA concentrations. Results: In cases who were preoperatively CEA positive, the maximum serum CEA levels for proximal colon, distal colon and rectal cancers were 384.8± 586.1ng/mL, 1395.7±1954.6ng/mL and 1343.4± 1478.3ng/mL, respectively. The maximum serum CEA level in cases of the proximal colon in preoperative CEA positive patients was lower than that in cases of distal colon or rectum. The average CEA DT on the proximal colon, distal colon and rectal cancers was 71.62±43.77 days, 31.07±15.98 days and 73.97±36.66 days, respectively. The CEA DT with distal colon cancers was also significantly shorter than that with proximal colon or rectal cancers (p<0.05, p<0.02). The CEA DT for lung metastasis was significantly longer than that for liver metastasis, locally or lymph node metastasis or multiple metastases (p<0.02, p<0.02, p<0.001). Conclusions: CEA DT serves to predict life expectancy for patients with recurrent colorectal cancers with different tumor distributions. We propose that precise measurements of serum CEA are needed so as not to overlook recurrent tumors. Detailed follow-up after operations is necessary for such patients, that CEA DT was noted in case of distal colon cancers.",
author = "Manabu Yamamoto and Yoshihiko Maehara and Yoshihisa Sakaguchi and Hiroyuki Mine and Takeharu Yamanaka and Daisuke Korenaga and Takeshi Okamura",
year = "2004",
month = "1",
day = "1",
language = "English",
volume = "51",
pages = "147--151",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "55",

}

TY - JOUR

T1 - Distributions in CEA Doubling Time Differ in Patients with Recurrent Colorectal Carcinomas

AU - Yamamoto, Manabu

AU - Maehara, Yoshihiko

AU - Sakaguchi, Yoshihisa

AU - Mine, Hiroyuki

AU - Yamanaka, Takeharu

AU - Korenaga, Daisuke

AU - Okamura, Takeshi

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Background/Aims: Serum carcinoembryonic antigen (CEA) is often measured during follow-up of patients surgically treated for colorectal cancer. We determined characteristic findings in serum CEA concentrations or CEA doubling time (DT) depending on the different tumor distributions in colorectal cancer patients. Methodology: Serum CEA levels were measured monthly until the patients expired in 32 colorectal cancers after operations. CEA DT was based on semilogarithmic plots of time courses of CEA concentrations. Results: In cases who were preoperatively CEA positive, the maximum serum CEA levels for proximal colon, distal colon and rectal cancers were 384.8± 586.1ng/mL, 1395.7±1954.6ng/mL and 1343.4± 1478.3ng/mL, respectively. The maximum serum CEA level in cases of the proximal colon in preoperative CEA positive patients was lower than that in cases of distal colon or rectum. The average CEA DT on the proximal colon, distal colon and rectal cancers was 71.62±43.77 days, 31.07±15.98 days and 73.97±36.66 days, respectively. The CEA DT with distal colon cancers was also significantly shorter than that with proximal colon or rectal cancers (p<0.05, p<0.02). The CEA DT for lung metastasis was significantly longer than that for liver metastasis, locally or lymph node metastasis or multiple metastases (p<0.02, p<0.02, p<0.001). Conclusions: CEA DT serves to predict life expectancy for patients with recurrent colorectal cancers with different tumor distributions. We propose that precise measurements of serum CEA are needed so as not to overlook recurrent tumors. Detailed follow-up after operations is necessary for such patients, that CEA DT was noted in case of distal colon cancers.

AB - Background/Aims: Serum carcinoembryonic antigen (CEA) is often measured during follow-up of patients surgically treated for colorectal cancer. We determined characteristic findings in serum CEA concentrations or CEA doubling time (DT) depending on the different tumor distributions in colorectal cancer patients. Methodology: Serum CEA levels were measured monthly until the patients expired in 32 colorectal cancers after operations. CEA DT was based on semilogarithmic plots of time courses of CEA concentrations. Results: In cases who were preoperatively CEA positive, the maximum serum CEA levels for proximal colon, distal colon and rectal cancers were 384.8± 586.1ng/mL, 1395.7±1954.6ng/mL and 1343.4± 1478.3ng/mL, respectively. The maximum serum CEA level in cases of the proximal colon in preoperative CEA positive patients was lower than that in cases of distal colon or rectum. The average CEA DT on the proximal colon, distal colon and rectal cancers was 71.62±43.77 days, 31.07±15.98 days and 73.97±36.66 days, respectively. The CEA DT with distal colon cancers was also significantly shorter than that with proximal colon or rectal cancers (p<0.05, p<0.02). The CEA DT for lung metastasis was significantly longer than that for liver metastasis, locally or lymph node metastasis or multiple metastases (p<0.02, p<0.02, p<0.001). Conclusions: CEA DT serves to predict life expectancy for patients with recurrent colorectal cancers with different tumor distributions. We propose that precise measurements of serum CEA are needed so as not to overlook recurrent tumors. Detailed follow-up after operations is necessary for such patients, that CEA DT was noted in case of distal colon cancers.

UR - http://www.scopus.com/inward/record.url?scp=10744225318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744225318&partnerID=8YFLogxK

M3 - Article

C2 - 15011851

AN - SCOPUS:10744225318

VL - 51

SP - 147

EP - 151

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 55

ER -